Perspective on Initial Therapy Selection
Dr. Hammers provides a perspective on the appropriateness of initial pembrolizumab + lenvatinib therapy based on guidelines.
EP: 1.Initial Clinical Impression Description
EP: 2.Perspective on Initial Therapy Selection
EP: 3.CLEAR Study Efficacy Data Description
EP: 4.Immunotherapy-Based Regimen Efficacy/Safety Updates
EP: 5.Factors in Treatment Selection
EP: 6.Managing Grade ≥3 Adverse Events
EP: 7.Toxicity Management Approach
EP: 8.Quality of Life Considerations
EP: 9.Future Management of Advanced RCC
George Explores Impact of Risk Status With Cabozantinib/Nivolumab in Advanced RCC
July 19th 2024During a Case-Based Roundtable® event, Daniel George, MD, discussed the results of the CheckMate 9ER trial across favorable, intermediate, and poor risk groups in patients with advanced renal cell carcinoma.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Comparing Long-Term Data for IO/IO and IO/TKI in Favorable-Risk mRCC
July 8th 2024During a Case-Based Roundtable® event, Rana McKay, MD, discussed the updated favorable-risk group data for 4 frontline combination trials in renal cell carcinoma in the first article of a 2-part series.
Read More
